Overview

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Status:
Not yet recruiting

Trial end date:
2026-12-17

Target enrollment:

Participant gender:

Summary

Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.

Phase:

Phase 4

Details

Lead Sponsor:

The Methodist Hospital Research Institute

Collaborator:

Genentech, Inc.

Treatments:

Atezolizumab
Bevacizumab